Renascience

Renascience Equity Ratio

The Equity Ratio of Renascience (4889.T) as of Nov 19, 2026 is 94.85 %. In the previous year, Equity Ratio was 91.92 % — a change of 3.18% (higher).

Equity Ratio

94.85 %

YoY

3.18%

Last updated:

Equity Ratio of Renascience is 2026 94.85 % . Equity Ratio of Renascience was 2025 91.92 % . It decreases by 3.18% higher compared to the previous year.

The Renascience Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2020
61.38 JPY
Jan 1, 2021
52.65 JPY
Jan 1, 2022
90.27 JPY
Jan 1, 2023
81.99 JPY
Jan 1, 2024
76.92 JPY
Jan 1, 2025
91.92 JPY
Jan 1, 2026
94.85 JPY
The Renascience Equity Ratio history
YEAREquity RatioYoY
94.85 %+3.18%
91.92 %+19.50%
76.92 %-6.18%
81.99 %-9.18%
90.27 %+71.47%
52.65 %-14.23%
61.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Equity Ratio of Renascience is 94.85 % in 2026.

Equity Ratio of Renascience changed from 91.92 % to 94.85 %, representing a 3.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Renascience since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Renascience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Renascience

All Key Metrics — Renascience